Cargando…

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction

Epithelial ovarian cancer (EOC) patients are generally diagnosed at an advanced stage, usually relapse after initial treatments, which include debulking surgery and adjuvant platinum-based chemotherapy, and eventually have poor 5-year survival of less than 50%. In recent years, promising survival be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Ying-Cheng, Lin, Po-Han, Cheng, Wen-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551835/ https://www.ncbi.nlm.nih.gov/pubmed/34722237 http://dx.doi.org/10.3389/fonc.2021.675972

Ejemplares similares

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma
por: Liu, Hangqi, et al.
Publicado: (2022)

Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?
por: Fountzilas, Elena, et al.
Publicado: (2021)

Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics
por: Yao, Qianlan, et al.
Publicado: (2022)

Radiation Metabolomics: Current Status and Future Directions
por: Menon, Smrithi S., et al.
Publicado: (2016)

Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
por: Zhang, Meng, et al.
Publicado: (2021)

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China
por: Ni, Jing, et al.
Publicado: (2022)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
por: Mekonnen, Negesse, et al.
Publicado: (2022)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions
por: Zhang, Zhuo, et al.
Publicado: (2015)

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
por: Mangogna, Alessandro, et al.
Publicado: (2023)

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020)

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
por: Roering, Pia, et al.
Publicado: (2022)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Xiong, Anwen, et al.
Publicado: (2021)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
por: De Lorenzo, Silvana B., et al.
Publicado: (2013)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
por: Quesada, Stanislas, et al.
Publicado: (2022)

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations
por: Quesada, Stanislas, et al.
Publicado: (2022)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
por: How, Jeffrey A., et al.
Publicado: (2021)

Signatures associated with homologous recombination deficiency and immune regulation to improve clinical outcomes in patients with lung adenocarcinoma
por: Shang, Xueqian, et al.
Publicado: (2022)

Ovarian cancer screening—Current status, future directions()
por: Menon, Usha, et al.
Publicado: (2014)

Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol
por: Liao, Hao, et al.
Publicado: (2022)

Is homologous recombination really an error-free process?
por: Guirouilh-Barbat, Josée, et al.
Publicado: (2014)

Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery
por: Yi, Huan, et al.
Publicado: (2022)

Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study
por: Zhou, Dongchen, et al.
Publicado: (2022)

Genitourinary Oncology: Current Status and Future Challenges
por: Bukowski, Ronald M.
Publicado: (2011)

Current status and future directions of ovarian cancer prognostic models
por: Kobayashi, Yusuke, et al.
Publicado: (2021)

Stereotactic partial breast irradiation in primary breast cancer: A comprehensive review of the current status and future directions
por: Takanen, Silvia, et al.
Publicado: (2022)

Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors
por: Gu, Peng, et al.
Publicado: (2022)

Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
por: Golesworthy, Bryn, et al.
Publicado: (2022)

Tumor homologous recombination deficiency assays: another step closer to clinical application?
por: Stecklein, Shane R, et al.
Publicado: (2014)

Current Options and Future Directions in Immune Therapy for Glioblastoma
por: Lynes, John, et al.
Publicado: (2018)

Current Status and Future Perspectives on the Etiology of Esophageal Adenocarcinoma
por: Thrift, Aaron P., et al.
Publicado: (2012)

Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients
por: Liu, Yixiao, et al.
Publicado: (2023)

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
por: da Cunha Colombo Bonadio, Renata Rodrigues, et al.
Publicado: (2018)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
por: van Wijk, Lise M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uf9fb0l8ak376sv9sipj3tvr4a